CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved.

Earnings season recap: the GSK share price is up, while the Tullow Oil share price tanks

The British drug maker saw its shares rally to a 17-year high after a strong third quarter, while the UK-based oil and gas company watched its stock plummet after downgrading its full-year production guidance.

London Stock Exchange Source: Bloomberg

Earnings season has delivered some highs and lows for various stocks, with GlaxoSmithKline (GSK) reaping the rewards of its joint venture with Pfizer in a move that has created a market leader in consumer healthcare and sent its shares soaring.

Meanwhile, Tullow Oil has seen its shares rocked after it was forced to downgrade its full-year production guidance due to issues at drill sites in Ghana.

GSK sees shares soar to 17-year high and could see further gains

GSK saw its share price close to a 17-year high of £17.82 after its third quarter (Q3) results last month.

The drug maker recorded strong sales growth in the trading period, prompting it to upgrade its full-year earnings forecast.

‘GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance,’ GSK CEO Emma Walmsley said.

‘This quarter we have continued to strengthen our pipeline and have advanced assets in Respiratory, HIV and, notably, Oncology, where we are on track to file three innovative medicines by year end, following positive pivotal trial data.’

Looking to trade GSK and Tullow Oil? Open a live or demo account with IG.

Analysts remain upbeat about the prospect of the stock not only returning to record levels but breaking above them.

Analysts at DZ Bank remain the most optimistic, reiterating their ‘buy’ rating for the stock in October and issuing a target price £20 a share. Liberum Capital and Credit Suisse gave a price target of £18.90 and £18 respectively.

Based on the stock’s current price of £17.14 as of 16:00 GMT on Tuesday, the three banks believe that GSK’s share price has a potential upside of between 5% to 16.6%.

GSK will unveil its fourth quarter results on February 5.

Tullow Oil sees share price tank after downgrading full-year production

Tullow Oil saw its share price plummet more than 30% last week after it downgraded its full-year production guidance.

Full-year 2019 oil production is forecast to average around 87,000 barrels of oil per day. This is slightly below previous guidance, primarily due to weaker-than-expected production performance at its operations in Ghana, with drilling suspended at its TEN fields site in July.

‘In West Africa, our non-operated assets continue to perform well,’ Tullow Oil CEO Paul McDade said. ‘However, Ghana production has not met our expectations this year and we are working closely with our Joint Venture Partners to ensure that both fields perform to their potential.’

You can go long or short GSK and Tullow Oil with IG using derivatives like CFDs.

However, the UK-based oil and gas company still has a bright future ahead of it, according to analysts from JP Morgan and Jefferies International.

Even though the pair downgraded their target price for the stock to 249p and 168p respectively in November, both banks believe that its share price has a potential upside of between 20% and 77.8% based on it trading at 140p as of 16:00 GMT on Tuesday.

The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer.

Act on share opportunities today

Go long or short on thousands of international stocks with CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take your position.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.